Overview

Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study

Status:
Completed
Trial end date:
2009-08-28
Target enrollment:
Participant gender:
Summary
GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate how much of the study drug gets into the brain. This will be done using Positron Emission Tomography (PET).
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline